Literature DB >> 9215168

Paraaortic lymph node biopsy: a twenty-year study.

J G Blythe1, E Edwards, P Heimbecker.   

Abstract

OBJECTIVES: Paraaortic lymph node biopsy is a controversial but proved technique to determine the extent of spread of cancers from the uterine cervix or endometrium. This article explores the following questions. Does the presence of positive paraaortic lymph nodes result in modification of the patient's therapy? Does the evidence gained from a paraaortic lymph note biopsy improve patient survival? STUDY
DESIGN: Five hundred sixty-eight patients had paraaortic lymph node sampling in conjunction with another operative procedure between 1976 and 1995. Five hundred seven (89.3%) of these patients had either endometrial or cervical cancer.
RESULTS: Paraaortic lymph node biopsies led to a survival rate of 9.1% for cervical carcinoma and 46.6% for endometrial carcinoma and were associated with acceptable morbidity.
CONCLUSIONS: We believe that paraaortic lymph node biopsies should be part of the routine evaluation of patients with gynecologic cancers. The knowledge gained by this procedure along with appropriately administered radiation therapy can save lives.

Entities:  

Mesh:

Year:  1997        PMID: 9215168     DOI: 10.1016/s0002-9378(97)70329-6

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  3 in total

Review 1.  Up-to-date management of lymph node metastasis and the role of tailored lymphadenectomy in cervical cancer.

Authors:  Noriaki Sakuragi
Journal:  Int J Clin Oncol       Date:  2007-06-27       Impact factor: 3.402

2.  The impact of the absolute number and ratio of positive lymph nodes on survival of endometrioid uterine cancer patients.

Authors:  J K Chan; D S Kapp; M K Cheung; K Osann; J Y Shin; D Cohn; P L Seid
Journal:  Br J Cancer       Date:  2007-07-31       Impact factor: 7.640

3.  Lymphadenectomy and adjuvant therapy in endometrial carcinoma: role of adjuvant chemotherapy.

Authors:  I Otsuka; T Kubota; T Aso
Journal:  Br J Cancer       Date:  2002-08-12       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.